Portal de Periódicos da CAPES

Rethinking Side Effects of the Selective Serotonin Reuptake Inhibitors: Sexual Dysfunction and Weight Gain

1998; Slack Incorporated (United States); Volume: 28; Issue: 2 Linguagem: Inglês

10.3928/0048-5713-19980201-10

1938-2456

Norman Sussman, David Ginsberg,

Sexual function and dysfunction studies

TREATING DEPRESSIONRethinking Side Effects of the Selective Serotonin Reuptake Inhibitors: Sexual Dysfunction and Weight Gain Norman Sussman, MD, , and , MD David Ginsberg, MD, , MD Norman Sussman, MD and David Ginsberg, MD Psychiatric Annals, 2013;28(2):89–97Published Online:February 01, 1998https://doi.org/10.3928/0048-5713-19980201-10View Full TextPDF ToolsAdd to favoritesDownload CitationsTrack Citations ShareShare onFacebookTwitterLinkedInRedditEmail SectionsMore1. Beasley CM, Sayler ME, Bosomworth C, Wernicke JF. High dose fluoxetine: efficacy and activating-sedating effects in agitated and retarded depression. J Clin Psychapharmacol. 1991; 11:166-174; Google Scholar2. Beasley CM, Sayler M, Weiss AM, et al. Fluoxetine: activating and sedating effects at multiple fixed doses. J Clin Psychopharmacol. 1992; 12:328-333). Google Scholar3. Coupland NJ, Bell CJ, Potokar JP. Serotonin reuptake inhibitor withdrawal. J Clin Psychopharmacol. 1996;16:356-362. Google Scholar4. Balon R. Selective serotonin reuptake inhibitors and sexual dysfunction. Primary Psychiatry. 1997;4:28-33. Google Scholar5. Patterson WM. Fluoxetine-induced sexual dysfunction. J Clin Psychiatry. 1993;54:71. Google Scholar6. Piazza LA, Markowitz JC, Kocsis JH, Leon AC, Portera L, Miller NL, Adler D. Sexual functioning in chronically depressed patients treated with SSRI antidepressants: a pilot study. Am J Psychiatry. 1997;154:1757-1759. Google Scholar7. Montejo-Gonzalez AL, LIorca G, Izquierdo JA, Ledesma A, Bousono M, Cal cedo A, Carrasco JL, Ciudad J, Daniel E, De la Gándara J, Derecho J, Franco M, Gomez MJ, Marcias JA, Martin T, Perez V, Sanchez JM, Sanchez S, Vicens E. SSRI-induced sexual dysfunction: fluoxetine, paroxetine, sertraline, and fluvoxamine in a prospective, multicenter, and descriptive clinical study of 344 patients. J Sex Marital Then 1997;23:176-194. Google Scholar8. Nemeth A, Arato M, Treuer T, Vandlik E. Treatment of fluvoxamine-induced anorgasmia with a partial drug holiday. Am J. Psychiatry. 1996; 153:1365. Google Scholar9. Rothchild AJ. Selective serotonin reuptake inhibitorsinduced sexual dysfunction: efficacy of a drug holiday. Am J Psychiatry. 1995-, 152:1514-1516 Google Scholar10. Cohen, 1992; Walker PW, Cole JO, Gardner EA, et al. Improvement in fluoxetine-associated sexual dysfunction in-patients switched to bupropion. J Clin Psychiatry. 1993; 54:459-465. Google Scholar11. Jacobsen FM, Comas-Diaz L. A double-blind placebo-controlled trial of yohimbine for treatment of SRI-induced sexual dysfunction. Presented at the APA 149th Annual Meeting, New York, New York, May 4-9,1996 (Abstract 716). Google Scholar12. Balogh S, Hendricks S, Kang J. Treatment of fluoxetineinduced anorgasmia with amantadine. J Clin Psychiatry. 1992; 53:212-213. Google Scholar13. Masand PS, Reddy N, Gregory R. SSRI-induced sexual dysfunction successfully treated with amantadine. Depression. 1994/1995; 2:319-321. Google Scholar14. Balon R, Yeragaani VK, Pohl R, Ramesh C. Sexual dysfunction and open trial of yohimbine. J Clin Psychiatry. 1993-, 54:209-212; Google Scholar15. Balon R. Intermittent amantadine for fluoxetine-induced anorgasmia. J Sex Martial Then 1996; 22:290-292. Google Scholar16. Norden MJ. Buspirone treatment of sexual dysfunction associated with selective serotonin re-uptake inhibitors. Depression. 1994;2:109-112; Google Scholar17. Bartlik BD, Kaplan HS. Psychostimulants apparently reverse sexual dysfunction secondary to selective serotonin re-uptake inhibitors. J Sex Marital Then 1995; 21:264-271. Google Scholar18. Labatte LA, Pollack MH. Treatment of fluoxetine-induced sexual dysfunction with bupropion: A case report. Ann Clin Psychiatry. 1994; 6:13-15. Google Scholar19. Aizenberg D, Zemishlany Z, Weizman A. Cyproheptadine treatment of sexual dysfunction induced by serotonin reuptake inhibitors. Clin Neuropharmacol. 1995; 18:320-324. Google Scholar20. Aizenberg D, Gur S, Zemishlany Z, Granek M, Jackmian P, Weizman A. Mianserin, a 5-HT^20 and 2 antagonist, in the treatment of sexual dysfunction induced by serotonin reuptake inhibitors. Clinical Neuropharmacology. 1997; 20:210-214. Google Scholar21. Arnott S, Nutt D. Successful treatment of fluvoxamine-induced anorgasmia by cyproheptadine. Br J Psychiatry. 1994; 164:838-839. Google Scholar22. Lauerma H. Successful treatment of citalopram-induced anorgasmia by cyproheptadine. Acta Psychiatr Scand. 1996; 93:69-70. Google Scholar23. Gitlin MJ. Treatment of sexual side effects with dopaminergic agents. J Clin Psychiatry. 1995; 56:24. Google Scholar24. Shrivastava RK, Shrivastava S, Overweg N, Schmitt M. Amantadine in the treatment of sexual dysfunction associated with selective serotonin reuptake inhibitors. J Clin Psychopharmacol. 1995;15:83-24. Google Scholar25. Nemeroff CB, Ninan PT, Ballenger J, et al. Double-blind multicenter comparison of fluvoxamine versus sertraline in the treatment of depressed outpatients. Depression. 1995; 3:163-169. Google Scholar26. Kiev A, Feiger A. A double-blind comparison of fluvoxamine and paroxetine in the treatment of depressed patients. J Clin Psychiatry. 1997; 58:146-152. Google Scholar27. Waldinger M. Dispatches. Primary Psychiatry. 1997. Google Scholar28. Zajecka J, Fawcett J, Schaff M, Jeffries H, Guy C. Therole of serotonin in sexual dysfunction: fluoxetine-associated orgasm dysfunction. J Clin Psychiatry. 1991; 51:25-27. Google Scholar29. Snyder S. Nitric oxide; first in a new class of neurotransmitters. Science. 1992; 257:494-496. Google Scholar30. Dawson TM; Dawson VL. Nitric oxide synthase: role as a transmitter/mediator in the brain and endocrine system. Annu Rev Med. 1996; 47:219-227. Google Scholar31. Cocks TM, Angus JA Endothelium-dependent relaxation of coronary arteries by noradrenaline and serotonin. Nature. 1983; 305:627-630, Google Scholar32. Model! JG. Repeated observations of yawning, clitoral engorgement, and orgasm associated with fluoxetine administration [letter]. J Clin Psychopharmacol. 1989; 9:63-65. Google Scholar33. Garcia-Campayo J, Sanz-Carrillo C, Lobo A. Orgasmic sexual experiences as a side effect of fluoxetine: a case report. Acia Psychiatr Scand. 1995;91:69-70. Google Scholar34. Cohen AJ, Fluoxetine-induced yawning and anorgasmia reversed by cyproheptadine treatment [letter]. J Clin Psychiatry. 1992; 53:174. Google Scholar35. McLean JD, Forsythe RG, Kapkin IA. Unusual side effects of clomipramine associated with yawning. Can J Psychiatry. 1983; 28:569-570. Google Scholar36. Bertschy G, Vande S, Bechter D. Bizourd P. Baillemants et excitation sexualle sous clomipramine. L'Encéphale. 1991; 17:515-517. Google Scholar37. Fluoxetine (Prozac) Product Information. Indianapolis: Eli Lilly; 1998. Google Scholar38. Paroxetine (Paxil) Product Information. Philadelphia: SmithKline Beecham; 1998. Google Scholar39. Elmore JL, Quattlebaum JT. Female sexual stimulation during antidepressant treatment. Pharmacotherapy. 1997; 17:612-616. Google Scholar40. Melis MR, Argiolas A. Role of central nitric acid in the control of penile erection and yawning. Prog Neuropsychopharmacol Biol Psychiatry. 1997; 21:899-922. Google Scholar41. Protais P, Windsor M, Mocaer E, Comoy E. Post-synaptic 5-HT1A receptor involvement in yawning and penile erections induced by apomorphine, physostigmine and mCPP in rats. Psychopharmacology (Berlin). 1995; 120:376-383. Google Scholar42. Poggioli R, Benelli A, Arletti R, Cavazzoti E, Bertolini A. Nitric oxide is involved in the ACTH-induced behavioral syndrome. Peptides. 1995;16:1263-1568. Google Scholar43. Melis MR, Succi S, Iannucci U, Argiolas A Prevention by morphine- and oxytocin-induced penile erection and yawning: involvement of nitric acid. Naunyn Schmiedebergs Arch Pharmacol. 1997; 355:595-600. Google Scholar44. Zvara P; Sioufi R; Schipper HM; Begin LR; Brock GB. Nitric oxide mediated erectile activity is a testosterone dependent event: a rat erection model. Ini J Impot Res. 1995; 4:209-219. Google Scholar45. Finkel MS, Laghrissi-Thode F, Pollock BG, Rong J. Paroxetine is a novel nitric oxide synthase inhibitor, Psychopharmacol Bull. 1996; 32:653-658. Google Scholar46. Galloway MP, West A, Norton CS, Chapman MA, Kocj S. Regulation of extracellular dopamine (DA) levels by endogenous serotonin (5HT), nitirc acid (NO), glutamate (GLU) or a novel environment. ACNP 36"' Annual Meeting, December 8-12, 1997, Hawaii). Google Scholar47. Renodon A, Boucher JL, Sari MA, Delaforge M, Ouazzani J, Mansuy D. Bromocriptine is a strong inhibitor of brain nitric oxide synthase: possible consequences for the origin of its therapeutic effects. ,FEBS Lett. 1997; 406:33-36. Google Scholar48. Reynolds RD. Sertraline-induced anorgasmia treated with intermittent nefazodone. J Clin Psychiatry. 1997; 58:89. Google Scholar49. Burra P, Ferraresso M, Cadrobbi R, Calabrese F, Cardin R, Pamigotto A, Carrara P, Rigotti P. Effect of L-arginine and oligotide on liver ischemia-reperfusion injury. Transplant Proc. 1997; 29:2992-2993. Google Scholar50. Nileson B, Yoshida T, Delbro D, Andius S, Friman S. Pretreatment with L-arginine reduces ischemia/reperfusion injury of the liver. Transplant Proc. 1997; 29:3111-3112. Google Scholar51. Pieper GM, Dondlinger LA. Plasma and vascular tissue arginine are decreased in diabetes; acute arginine supplementation restores endothelium-dependent relaxation by augmenting cGMP production. J Pharmacol Exp Ther. 1997; 283:684-691. Google Scholar52. Brown TM, Skop BP. Nitroglycerin in the treatment of the serotonin syndrome. Ann Pharmacotherapy. 1996; 30:191-192. Google Scholar53. Klein, 1989. Google Scholar54. De Wilde J, Spiers R, Mertens C, Bartholome F, Schotte G, Leyman S. A double-blind, comparative, multicentre study comparing paroxetine with fluoxetine in depressed patients. Acta Psychiatr Scand. 1993; 87:141-145. Google Scholar55. Food and Drug Administration 1993, Summary basis of approval for Paxil (paroxetine). Available from the Freedom of Information Services Inc., 12315 Wilkins Avenue, Rockville, MD 20852-1877. Google Scholar56, Fisher S, Kent TA, Bryant SG. Postmarketing surveillance by patient self-monitoring: Preliminary data for sertraline versus fluoxetine. J Clin Psychiatry. 1996; 56:288-296. Google Scholar57. Amsterdam J, Garcia-Espana F, Goodman D, Hooper MB1 Hornig-Rohan M. Breast enlargement during SSRI therapy [abstract]. Biol Psychiatry. 1997; 41:28S. Google Scholar58. Szarek BL, Brandt DM. A comparison of weight changes with fluoxetine, desipramine, and amitriptyline: A retrospective study of psychiatric inpatients. J Nerv Ment Dis. 1993; 181:702-704. Google Scholar59. Harto NE, Spera KF, Branconnier RJ. Fluoxetine-induced reduction of body mass in patients with major depressive disorder. Psychopharmacol Bull. 1988; 24:220-223. Google Scholar60. Wadden TA, Bartlett SJ, Foster GD, Greenstein RA, Wingate BJ, Stunkard AJ, Letizia KA. Sertraline and relapse prevention training following treatment by verylow-calorie diet: a controlled clinical trial. Obesity Res. 1995; 3:549-557. Google Scholar61. Fogelson DL. Weight gain during fluoxetine treatment. J Clin Psychopharmacol. 1991; 11:220-221. Google Scholar62. Bouwer CD, Harvey BH. Phasic craving for carbohydrate observed with Citalopram. Int Clin Psychopharmacol. 1996; 11:273-278. Google Scholar63. Fichtner CG, Braun BG. Hyperphagia and weight loss during fluoxetine treatment. Ann Pharmacother. 1994; 12:1350-1352. Google Scholar64. Fernstrom M. Druge that cause weight gain. Obesity Res. 1995; 3(suppl 4):435S-439S. Google Scholar65. Ayd FJ. A critical appraisal of chlordiazepoxide. J Neuropsychiatry. 1962; 3:177-180; Google Scholar66. Greenblatt DJ, Shader RI. Benzodiazepines in Clinical Practice. New York: Raven Press; 1974. Google Scholar67. Haney M, Comer SD, Fischman MW, Foltin RW. Alprazolam increases food intake in humans. Psychopharmacology. 1997; 132:311-314. Google Scholar68. Palvimaki E-P, Roth BL, Majasuo H, et al. Interactions of selective serotonin reuptake inhibitors with the serotonin 5-HT2C receptor. Psychopharmacology. 1996; 126: 234-240. Google Scholar69. Sargent PA, Sharpley AL, WiUiams C, Goodatt EM, Cowen PJ. 5-HT2C receptor activation decreases appetite and body weight in obese subjects. Psychopharmacology. 1997; 133:309-312. Google Scholar70. Burns CM, Chu H, Rueter SM, Hutchinson LK, Canton H, Sanders-Bush E, Emeson RB. Regulation of serotonin2C receptor G-protein coupling by RNA editing, [letter]. Nature. 1997; 387:303-308. Google Scholar71. Tecott LH, Sun LM, Akana SF, et al. Eating disorders and epilepsy in mice lacking 5-HT2C serotonin receptors. Nature. 1995; 374:542-546. Google Scholar72. Wong DT, Threlkeld PG, Robertson DW. Affinities of fluoxetine, its enanthomers, and other inhibitors of serotonin uptake for subtypes of serotonin receptors. Neuropsychopharmacology. 1991; 5:43-47. Google Scholar73. Ni YG, Miledi R. Blockage of 5HT2C serotonin receptors by fluoxetine (Prozac). Proc Natl Acad Sci USA. 1997; 94:2036-2040. Google Scholar74. Laakso A, Palvimaki E-P, Kuoppamaki M, Syvalahti E, Hietala J. Chronic Citalopram and fluoxetine treatments upregulate 5-HT2C receptors in the rat choroid plexus. Neuropsychopharmacology. 1996; 15:143-151. Google Scholar75. Maj J, Bijak M, Dziedzicka-Wasylewska M, et al. The effects of paroxetine given repeatedly on the 5-HT receptor subpopulations in the rat brain. Psychopharmacology. 1996; 127:78-82. Google Scholar76. Huether G, Zhou D, Schmidt S, Wiltfang J, Rüther. Long-term food restriction down-regulates the density of serotonin transporters in the rat frontal cortex. Biol Psychiatry. 1997;41:1174-1180. Google Scholar77. Curara G, Gibson EL, Oluyomi AO. Appetite suppression by commonly used drugs depends on 5-HT receptors but not on 5-HT availability. Trends Pharmacol Sci. 1997; 18:21-25. Google Scholar78. Lightowler s, Wood M, Brown T, Glen A, Blackburn T, Tulloch I, Kennett G. An investigation of the mechanism responsible for fluoxetine-induced hypophagia in rats. Eur J Psychopharmacol. 1996; 296:137-143. Google Scholar Previous article Next article FiguresReferencesRelatedDetails Request Permissions InformationCopyright 2013, SLACK IncorporatedPDF download • 16.9 MB